Results 1 to 10 of about 2,116,690 (282)

Pharmacogenetic study of deferasirox, an iron chelating agent. [PDF]

PLoS ONE, 2013
Transfusion-associated iron overload induces systemic toxicity. Deferasirox, a convenient long acting oral agent, has recently been introduced in clinical practice with a promising efficacy.
Ji Won Lee, Hyoung Jin Kang, Ji-Yeob Choi, Nam Hee Kim, Mi Kyung Jang, Chang-Woo Yeo, Sang Seop Lee, Hyery Kim, June Dong Park, Kyung Duk Park, Hee Young Shin, Jae-Gook Shin, Hyo Seop Ahn   +12 more
doaj   +7 more sources

Therapeutic potential of silymarin as a natural iron‐chelating agent in β‐thalassemia intermedia [PDF]

Clinical Case Reports, 2022
Abnormal iron accumulation in vital organs is one of the major complications of β‐thalassemia intermedia (β‐TI). Silymarin, a flavonolignan isolated from Silybum marianum, significantly decreases the serum ferritin levels of β‐TI patients.
Nahid Reisi, Nafiseh Esmaeil, Marjan Gharagozloo, Behjat Moayedi   +3 more
doaj   +2 more sources

Retraction Note: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox [PDF]

BMC Cancer, 2023
This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12885-023-11677-6.
Shogo Amano, Seiji Kaino, Shuhei Shinoda, Hirofumi Harima, Toshihiko Matsumoto, Koichi Fujisawa, Taro Takami, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida   +9 more
doaj   +2 more sources

Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox

BMC Cancer, 2020
Background Iron is required for cellular metabolism, and rapidly proliferating cancer cells require more of this essential nutrient. Therefore, iron regulation may well represent a new avenue for cancer therapy.
Shogo Amano, Seiji Kaino, Shuhei Shinoda, Hirofumi Harima, Toshihiko Matsumoto, Koichi Fujisawa, Taro Takami, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida   +9 more
doaj   +2 more sources

Hearing assessment in transfusion dependent beta-thalassemia children on oral iron chelating agent [PDF]

BMC Pediatrics
Background Hearing deficit is one of the side effects of 1st generation iron chelators in β-thalassemia, however the risk of hearing deficits following 2nd generation iron chelators is not well known. Aim To assess hearing status of Transfusion Dependent
Wafaa E. I. Mohamed, Marwa Waheed Tolba, Yara Khalid Abuelfadl, Abeer Mohamed Elgendy, Heba G. A. Ali   +4 more
doaj   +2 more sources

3-Chloro-N′-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy [PDF]

Frontiers in Pharmacology, 2018
Despite the discovery and development of novel therapies, cancer is still a leading cause of death worldwide. In order to grow, tumor cells require large quantities of nutrients involved in metabolic processes, and an increase in iron levels is known to ...
Federica Sarno, Chiara Papulino, Gianluigi Franci, Gianluigi Franci, Jeanette H. Andersen, Bastien Cautain, Colombina Melardo, Lucia Altucci, Angela Nebbioso   +8 more
doaj   +2 more sources

Nematode-trapping fungus Arthrobotrys oligospora is hungry for iron-chelating agent COQ7 of nematodes [PDF]

Natural Products and Bioprospecting
Iron homeostasis is critical for the survival of almost all organisms, yet its dysregulation is often caused by a synergistic effect of genetic and environmental factors.
Qunfu Wu, Jiao Zhou, Donglou Wang, Songhan Xue, Ling Li, Li Wu, Junxian Yan, Xuemei Niu   +7 more
doaj   +2 more sources

Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox [PDF]

BMC Cancer, 2023
Shogo Amano, Seiji Kaino, Shuhei Shinoda, Hirofumi Harima, Toshihiko Matsumoto, Koichi Fujisawa, Taro Takami, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida   +9 more
doaj   +2 more sources

Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta-analysis. [PDF]

CNS Neurosci Ther
Negida A, Hassan NM, Aboeldahab H, Zain YE, Negida Y, Cadri S, Cadri N, Cloud LJ, Barrett MJ, Berman B.   +9 more
europepmc   +2 more sources

A Case of Secondary Hemochromatosis

Case Reports in Clinical Practice, 2021
A 28-year-old woman with a history of transfusion-dependent thalassemia major who did not receive any iron-chelating agent presented with symptoms of iron overload with marked diffuse increased liver density.
Narjes Zarei Jalalabadi, Morteza Daraei, Samaneh Parsa, Neda Faraji   +3 more
doaj   +1 more source